JPM 2022: Editas, which caught flak in 2021 for limited gene editing data, will try to layer on the proof in 2022

Editas Medicine released a tiny drop of data last year as a proof of concept for its gene editing platform. Now, the CRISPR/Cas9 biotech will spend 2022 trying to back that up.

We’re going to hear more about EDIT-101, the gene editing company’s vision loss therapy, this year, according to…